Compare Google Inc (GOOG) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Google Inc vs Moderna, Inc. — how do they compare? Google Inc trades at $350.76 (market cap $4.24T), while Moderna, Inc. trades at $219.06 (market cap $78.65B). The key difference: Google Inc is far larger — about 53.9× Moderna, Inc.'s market cap, and Google Inc pays a 0.26% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Google Inc for 137 Days and Moderna, Inc. for 59 Days on average.
| GOOG | MRNA | |
|---|---|---|
Market Cap | $4.24T | $78.65B |
Volume | 13,937,902 | 37,373,437 |
Sector | Media | Health |
52-Week High | $399.06 | $203.46 |
52-Week Low | $237.49 | $22.36 |
Typical Hold Time | 137 Days | 59 Days |
Enterprise Value | $4.13T | $74.80B |
Dividend Yield | 0.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOG) trades at $350.02, up 0.76% with strong technical momentum and bullish moving average signals. The company demonstrates exceptional financial performance with 32.8% net margins and consistent earnings beats, though significant capital expenditures have led to negative free cash flow concerns. Analyst consensus remains overwhelmingly positive with 87% buy ratings and a $435.24 price target, representing 24% upside potential from current levels.
The outlook remains favorable given Alphabet's dominant market position and AI leadership, though investors face risks from escalating capital spending, regulatory scrutiny, and multiple class-action lawsuits. The stock's current valuation at 17.3x P/E appears reasonable relative to growth prospects, supported by robust cash flow generation and expanding cloud revenue streams.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Google Inc
Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.
Read more on GOOG →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
